You are here

INHERENTLY CONTROLLED MAGNETIC BEARING ROTARY BLOOD PUMP

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 2R44HL065819-02
Agency Tracking Number: HL065819
Amount: $0.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 2002
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
FOSTER-MILLER TECHNOLOGIES, INC. 431 NEW KARNER RD
ALBANY, NY 12205
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 HSIANG CHEN
 (518) 456-9919
 MCHEN@FOSMILTECH.COM
Business Contact
 DOUGLAS MCCAULEY
Phone: (518) 456-9919
Email: DMCCAULEY@FOSMILTECH.COM
Research Institution
N/A
Abstract

Description (provided by applicant): The goal of this Phase II project is to
demonstrate the prototype of a fully implantable rotary ventricular assist
device (VAD). This pump utilizes the advanced three-dimensional magnetic
suspension for the rotor demonstrated during Phase I. This bearing system
requires neither position sensors nor active feedback electronics, resulting in
the simplest 3-0 magnetic bearing available for blood pumps. The bearing coils
form part of a tuned inductance-capacitance-resistance (LCR) circuit. A sine
wave generator powers the coil. Motion of the rotor varies the inductance and
therefore tuning of the circuit such that changes in electrical current flow
always occur to oppose the direction of motion. Control of the rotor position
is inherent in the bearing construction and Eamshaw?s Law is satisfied. Phase I
demonstrated that this bearing construct can be dynamically stable, low in
power consumption, and adequately stiff to handle externally applied shock and
vibration loads. During Phase II, the program will advance to design and
develop a prototype implantable rotary VAD and electronics package and perform
in-vivo tests and in-vitro endurance tests. Successful completion will lead
directly to a Phase Ill effort and ultimately FDA approval for clinical trials.

PROPOSED COMMERCIAL APPLICATION: Heart disease remains the leading cause of death and disability in the United States. Of the 600,000 Americans who die each year due to heart-related problems, about 30,000 to 60,000 could probably be saved with heart transplants. However, the shortage of donor hearts precludes this, and has stimulated the development of many mechanical heart assist and replacement devices. Should mechanical assist pumps prove sufficiently safe and reliable, the potential use to improve the quality of life for cardiac-impaired patients dramatically expands the market.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government